Julie Papanek Grant

Julie brings operational experience from biotechnology and healthIT and currently sits on the board of Protagonist Therapeutics (PTGX). Julie has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. The San Francisco Business Times named Julie to the 40 Under 40 Class of 2017 in recognition of her contributions to Bay Area business. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development. This included creating commercial brand plans, forecasting, and recommending modifications to Phase III trials designs for marketed and pipeline oncology products. She advises a number of digital health and BioPharma companies on business development and go to market strategy. Personally, Julie has a particular passion for consumer access and affordability to care. Julie holds an MBA from Stanford's Graduate School of Business, where she was the teaching assistant for the Biodesign Innovation course and an officer of the Healthcare Club. Previously, she earned an MPhil from Cambridge University in BioScience Enterprise and a B.S. from Yale University in Molecular Biophysics and Biochemistry.